GHR Foundation
  • Impact Areas
    • Global Development >
      • Children in Families
      • Inter-Religious Action
      • Sister Support
    • Education >
      • Catholic Schools
      • Higher Education
    • Alzheimer's Prevention
  • BridgeBuilder
    • Overview
    • 2017 Top Ideas >
      • Peace Direct
      • BioCarbon Engineering
      • LIFT Chicago
      • Local Youth Corner Cameroon
      • NaTakallam
    • 2018 Top Ideas >
      • This is My Backyard
      • Found in Translation
      • Producers Direct
      • War Child Canada
      • My Choices Foundation
    • 2019 Top Ideas >
      • Top Manta
      • Five One Labs
      • SAMA for All
      • Talent Beyond Boundaries
      • FaithAction
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • FAQs
    • Grants & Financials
  • Contact

Pioneering Alzheimer’s Prevention Study Starts Enrollment

8/29/2016

 
Picture
GHR’s Health initiative partners with organizations using innovative trials to pursue the prevention of Alzheimer’s disease. One such trial is the Alzheimer’s Prevention Initiative (API) Generation Study which recently began enrollment in high-risk older adults to validate the use of genetic screening and identify an effective approach to prevent the disease.

Led by Dr. Eric Reiman and Dr. Pierre Tariot of Banner Alzheimer’s Institute (BAI), this pioneering multi-site prevention study is working to determine whether two investigational anti-amyloid compounds—an active immunotherapy and an oral medication—can prevent or delay the emergence of Alzheimer’s symptoms in people at a high genetic risk of developing the disease. The study will involve more than 1,300 cognitively healthy adults, age 60 to 75, who have inherited a copy of the e4 type of the apolipoprotein (APOE) gene from each parent. Roughly one in four people carry a single copy of the gene, which is strongly linked to late-onset Alzheimer’s.

The Generation Study is part of the API, an international collaborative led by BAI to accelerate the evaluation of promising treatments. The study is sponsored by Swiss pharmaceutical company Novartis and Thousand Oaks, Calif.-based biotechnology company Amgen in collaboration with BAI, with funding from the National Institute on Aging—part of the National Institutes of Health—as well as GHR, Alzheimer’s Association, Fidelity Biosciences Research Institute and Banner Alzheimer’s Foundation.

To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on the prevention of Alzheimer’s disease, contact us.

DIAN-TU Trials Expand Internationally

7/21/2016

 
Picture
GHR Foundation’s Health initiative partners with organizations pursuing the prevention of Alzheimer’s disease, targeting funding to improve some of the largest research efforts in the field. One such partner is Washington University’s Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). The DIAN-TU was formed to design and implement prevention trials for dominantly inherited Alzheimer’s disease, caused by a genetic mutation.

This rare form of Alzheimer’s disease results in early-onset of the disease with symptoms starting as early as a person’s 30s and 40s. The DIAN-TU launched a prevention study in this rare population testing experimental drug therapies that may stop the progression of Alzheimer’s disease before symptoms emerge. The trial is currently fully enrolled for the first two drugs and operational in 24 sites across six countries, with interim results expected in 2017 and final results by 2019.

The DIAN-TU builds on Washington University's Dominantly Inherited Alzheimer Network Observational study which collects observational data on persons with these genetic mutations.  The DIAN study is operational in 17 sites across six countries, many of which are also DIAN-TU trial sites.

Washington University is currently planning its DIAN-TU Next Generation trials, which will test two additional potential treatments and novel diagnostic approaches with the dominantly inherited Alzheimer’s disease population. The DIAN-TU project gained attention recently in Germany during the first meeting of German families with the mutations. Attendees were informed about Alzheimer’s clinical trials and the DIAN-TU trials in particular, and had the opportunity to pose questions to researchers. All eligible attendees indicated interest in enrolling in future studies. Given the requirement for multiple sites to meet recruitment goals in this rare population, the participation of the German families is an important step for the DIAN-TU Next Generation Trials.

To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on the prevention of Alzheimer’s disease, contact us. To learn more about the DIAN-TU Study, visit www.dianexr.org or call 1-844-DIAN-EXR (844-342-6397).

DIAN-TU Study Profiled on PBS

3/2/2016

 
Picture
GHR Foundation’s Health Initiative is targeting funding to improve some of the largest Alzheimer’s prevention research efforts in the field, including Washington University Medical School’s DIAN-TU Study. This study is quickly evaluating potential prevention treatments among people with a rare genetic trait that causes the onset of the devastating disease in the prime of their lives.

The DIAN-TU Study was recently profiled by PBS’ SciTech Now program, which interviewed Dr. Randall Bateman, Dr. John Morris and a participant of the study. The DIAN-TU segment is the first of three in the 26-minute show, and continues in an interview at the end. This touching and informative profile illustrates not only the science behind the study, but the implications of the disease and what motivates participants.

​To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health for the prevention of Alzheimer’s disease, contact us.

How the Collaboration for Alzheimer’s Prevention is Improving Trials

1/7/2016

 
Picture
GHR’s Health Initiative has committed more than $17 million over 5 years to scaling up important Alzheimer’s disease prevention research already underway. The Foundation is targeting funding to improve some of the largest research efforts in the field, including Washington University's DIAN-TU Study, which is quickly evaluating potential prevention treatments among those who are most likely to develop the disease, and Harvard University's A4 Study, which is working toward FDA approval for prevention therapy in the general population.

A recent Nature article highlights the importance of preclinical treatments, like DIAN-TU, which are initiated in cognitively unimpaired at-risk people, and are intended to postpone, reduce the risk of or completely prevent the clinical onset of Alzheimer’s. The authors argue that we need faster ways to evaluate these treatments, new ways to collaborate towards common goals and determination to expedite preclinical trials.

One useful tool for accelerating the initiation and performance of these trials is Collaboration for Alzheimer’s Prevention (CAP), a convening and consensus-building initiative co-founded by DIAN-TU and A4, among others. Important strides made by CAP include:
  • Development of trial outcomes, including cognitive and clinical endpoints and biomarkers
  • Standardization of sample and data collection, such as the use of tau imaging in all CAP trials
  • Participant recruitment and retention through the development of a registry
  • Data and sample sharing mechanisms

​These developments help carry out Alzheimer’s prevention trials with care, thoroughness and maximum impact. ​While all research is uncertain, the potential to turn the tide and provide hope for all families that face Alzheimer’s has never been more promising.  To learn more about GHR’s Alzheimer’s prevention funding efforts, contact us.

DIAN-TU Enrollment Complete

12/8/2015

 
Picture
GHR Foundation’s Health Initiative is dedicated to a game-changing undertaking—the prevention of Alzheimer’s disease. The Foundation is targeting funding to improve some of the most important research efforts in the field, including Washington University's DIAN-TU Study. This trial focuses on rapid testing of prevention therapies among families that are most likely to develop the disease.
​
Recently, DIAN-TU announced it has completed participant enrollment for the first stage of the trial. This enrollment milestone means the first biomarker results will be available at the end of 2016, with the final cognitive endpoint expected in late 2019. This first stage will determine the effects of two drugs targeting amyloid plaques, which are believed by some scientists to be the first step in the process leading to cognitive impairment.
 We will keep going until there are drugs to effectively prevent and treat Alzheimer’s disease.” –Dr. Randall Bateman, Washington University
The DIAN-TU team is working with the next generation of innovative drugs and study designs, and expects enrollment for new drugs. To learn more about DIAN-TU and GHR Foundation’s involvement in other innovative Alzheimer’s prevention trials, contact us.

GHR receives the Stone Award for Alzheimer’s Research

8/18/2015

 
Picture
GHR Foundation’s Health Initiative is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on a game-changing undertaking—the prevention of Alzheimer’s disease. Recently, GHR Foundation was awarded the Jerome H. Stone Philanthropy Award for Alzheimer’s Research for its philanthropic efforts to support Alzheimer’s disease prevention research. The award was also presented to the MetLife Foundation, which works with experts to assist low-income individuals facing Alzheimer’s.

The recognition was presented at the Annual Alzheimer’s Association International Conference in memory of Alzheimer’s Association founder Jerome Stone, who passed away earlier this year. Fred Miller accepted the award on behalf of the Foundation at the opening plenary session, attended by more than 4,000 global researchers, donors and advocates. This year’s Alzheimer’s Conference also saw the release of promising new prevention research results.  To see a summary of news from the Conference, read the Alzheimer’s Association news release.

We are happy to accept this recognition as an innovative partner in the fight against Alzheimer’s. The Stone Award strengthens GHR’s credibility as we cultivate important public- and private-sector partners. To learn more about how GHR’s Health Initiative, contact us.

New GHR Case Study of the Mayo Clinic Study of Aging

6/19/2015

 
GHR Foundation is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on a game-changing undertaking – the prevention of Alzheimer’s disease. One important study GHR is supporting is The Mayo Clinic Study of Aging, which is working to define the impact of Alzheimer's on the population and develop a screening approach to identify those at risk.

View a case study on The Mayo Clinic's innovative research by clicking image below.
GHR supports innovative new approaches to address the impact of Alzheimer’s disease. If you are interested in learning more about GHR’s Health Initiative, contact us.

New Grant to Support Launch of APOE4 Alzheimer’s Trial

6/1/2015

 
GHR Foundation is joining forces with philanthropic and industry partners to fund groundbreaking Alzheimer’s prevention research. One such partnership is the APOE trial, a prevention study that will launch by early 2016 and last five years. GHR has partnered with the Alzheimer’s Association and Fidelity Biosciences Research Initiative to provide $10 million in new research funding to support the study.

The API APOE4 trial, conducted by the Banner Alzheimer’s Institute in Phoenix, Arizona, is focused on how two new therapies may prevent or delay the development of Alzheimer’s symptoms in a population known to be at high risk for the disease because of their age and genetic status. The trial will test two different potential approaches to see if one or both can prevent the development of memory and thinking symptoms of Alzheimer’s.

The new funding will support three aspects of the API APOE4 trial, including the expansion of the Alzheimer’s Prevention Registry, the evaluation of two remote genetic counseling approaches and new scans including Tau PET imaging, amyloid PET imaging and FDG-PET imaging. If successful, the trial will not only to evaluate investigational prevention therapies, but will help find faster ways to evaluate promising prevention therapies in the future.

To learn more about how the Foundation is targeting funding to improve some of the largest research efforts in the field, contact us.
Picture

Remembering Our Founder

4/24/2015

 
Picture
By Amy Goldman, GHR Foundation CEO & Chair

Today marks the one year anniversary of our founder, Gerald (Gerry) Rauenhorst’s passing. Appropriately, GHR staff are spending the day volunteering in the community as part of the fourth annual Founder’s Day. There could be no more fitting tribute to Gerry’s legacy.

Gerry was born in Olivia, Minn., in 1927, the son of tenant farmers and one of eight children. Gerry learned early practical lessons about the necessity of hard work and faith, anchoring his life on the words of St. Augustine: “I shall work as if everything depended on me; I shall pray as if everything depended on God.” He married his partner in life and philanthropy Hanky Schmoll in 1950 and spent the next six decades building a family and business, ever-mindful of their shared commitment to Catholic social values.

As I reflect on the last year, I know Gerry would be satisfied and content with what we have achieved. Together, with our valued partners, we have: 
  • Awarded more than $17 million in transformative grants to 103 organizations worldwide, in the areas of health, education and global development.
  • Supported breakthrough Alzheimer’s studies that have the potential to prove prevention is possible.
  • Approved funding to bring City Connects to the Twin Cities, offering urban Catholic school students the support they need to truly succeed – whether that be housing support, food shelf access or tutoring.
  • Continued to advance our focus on innovative global development grant making by partnering with Catholic sisters, advancing inter-religious action and focusing on children and families in Zambia and Cambodia. 
  • Started a new chapter in GHR’s new offices, located in downtown Minneapolis, providing the ability to connect with grantees and partners in a powerful new way.

While the world is profoundly changed through his absence, I’m confident Gerry’s legacy lives on through the work we do. To learn more, visit our history and legacy page.

Alzheimer's Research Making Headlines

4/6/2015

0 Comments

 
Picture
From People Magazine: Alzheimer’s patient Sonia Cardona and her caregiver and daughter Daisy Duarte.
The fight against Alzheimer’s disease is making headlines. Fueled by research advances and popular culture attention, GHR-funded projects targeting Alzheimer's prevention are building public awareness. Grants making headlines include:
  • DIAN-TU Study: GHR is one of the funders of the Washington University study to quickly evaluate potential prevention treatments among people most likely to develop the disease. Trial participant Daisy Duarte was recently profiled in People Magazine. This article, along with Oscar attention for “Still Alice”—a film about a woman with early-onset Alzheimer’s—is helping to bring prevention research into the public spotlight.
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Study (A4): GHR is also contributing to the A4 Harvard study that is designed to identify and treat patients in the earliest stages of Alzheimer's, before memory loss begins. Recently, A4 researchers conducted the first scans in a clinical trial for the presence of the protein tau, which forms toxic tangles of nerve fibers associated with Alzheimer's. The addition of tau imaging into this trial was directly funded by GHR and is our primary contribution to the study. The breakthrough scans will enable researchers to see the effects of an experimental drug on both amyloid plaques and tau tangles for the first time, potentially leading to more effective prevention and treatments.

Recent headlines document important milestones in the fight against Alzheimer's. GHR supports research that inspires hope among those impacted by the disease and advances opportunities for real results. For more information, contact us.
0 Comments
<<Previous

    Categories

    All
    Africa
    Alzheimer's
    Annual Report
    BridgeBuilder
    Cambodia
    Catholic Schools
    Central African Republic
    Children In Families
    Coverage
    COVID-19
    Design Build
    Education
    Faith & Development
    Global
    Global Development
    Health
    Higher Education
    Inter-Religious Action
    Kenya
    Legacy
    Myanmar
    Nepal
    Nigeria
    Podcast
    Sister Support
    Solutions
    Uganda
    U.S.
    Work Of The Church
    Zambia

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    December 2018
    November 2018
    October 2018
    September 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    August 2017
    July 2017
    May 2017
    April 2017
    March 2017
    January 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    August 2014
    July 2014
    May 2014
    April 2014
    March 2014
    October 2013
    December 2012

    RSS Feed

CONNECT WITH US

IMPACT AREAS  |  NEWS  |  ABOUT  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2020 GHR FOUNDATION
All Rights Reserved.